Matches in Nanopublications for { ?s ?p "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP561898.RADdCXmBPbs0n-fnygp36duz2cVah6c0KSx5ZETtFl_hA130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561898.RADdCXmBPbs0n-fnygp36duz2cVah6c0KSx5ZETtFl_hA130_provenance.
- NP561895.RA5-1wPMULPNI-8b5Y6jficfmgFFOlEkOiYEz6oNW1NUs130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561895.RA5-1wPMULPNI-8b5Y6jficfmgFFOlEkOiYEz6oNW1NUs130_provenance.
- NP561900.RAWOAsT0id8L8aBOtfy-2sqyyllHZtAW4hXFoL0uKQTe4130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561900.RAWOAsT0id8L8aBOtfy-2sqyyllHZtAW4hXFoL0uKQTe4130_provenance.
- NP561901.RAR9Uc1JQSsn17vy4bYYUjrBBRYuuZD6joNGkHrO4c2jg130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561901.RAR9Uc1JQSsn17vy4bYYUjrBBRYuuZD6joNGkHrO4c2jg130_provenance.
- NP561886.RANoOAE_NH7kl15SqqDHQUAGFsx5G6ehTM2tHykT3-akc130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561886.RANoOAE_NH7kl15SqqDHQUAGFsx5G6ehTM2tHykT3-akc130_provenance.
- NP561890.RAJ_ro9XA9b3KBqxlJYiSZF7kWAG4Xq0EXfXDobMhRtPU130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561890.RAJ_ro9XA9b3KBqxlJYiSZF7kWAG4Xq0EXfXDobMhRtPU130_provenance.
- NP561891.RAHDHTgeX9wlg0PlhbqLjuyr9kU5bVq2qypb-gF21kzEE130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561891.RAHDHTgeX9wlg0PlhbqLjuyr9kU5bVq2qypb-gF21kzEE130_provenance.
- NP561893.RAgKoyuVnuMiY4RQMhnMF8LoBmaVmu9O8zj_SrXuljYhA130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561893.RAgKoyuVnuMiY4RQMhnMF8LoBmaVmu9O8zj_SrXuljYhA130_provenance.
- NP561899.RAhViamViiQCo6lZO0OrdlgdYHODlJjMCmiP0VmuHzjiE130_assertion description "[We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP561899.RAhViamViiQCo6lZO0OrdlgdYHODlJjMCmiP0VmuHzjiE130_provenance.